Gamble of the week: ground-breaking biotech stock

In five or ten years' time, this biotech outfit could be a household name, says Paul Hill, and looks a good long-term bet.

Unless you're a medical expert, you'll probably never have heard of ISIS Pharmaceuticals. But in five to ten years' time, assuming things go according to plan, this biotech outfit could be a household name. That's because it has developed a ground-breaking new technique called 'antisense'.

Many of today's most common diseases such as cardiovascular problems, cancer and diabetes are caused by 'bad' proteins being wrongly produced in the human body. Current drugs attack these dangerous cells, but the problem is that the side effects can be extreme, and the efficacy poor.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

Paul gained a degree in electrical engineering and went on to qualify as a chartered management accountant. He has extensive corporate finance and investment experience and is a member of the Securities Institute.

Over the past 16 years Paul has held top-level financial management and M&A roles for blue-chip companies such as O2, GKN and Unilever. He is now director of his own capital investment and consultancy firm, PMH Capital Limited.

Paul is an expert at analysing companies in new, fast-growing markets, and is an extremely shrewd stock-picker.